Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 3/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19555015 | 0.83 | GABRG2 (0.43) | GABRG2GABRB3GABRA5GABRA3MAOB | |
| SCHEMBL15253770 | 0.82 | L3MBTL1 (0.51) | GABRG2GABRB3GABRA5GABRA3KDM4E | |
| SCHEMBL19554539 | 0.79 | MAOB (0.48) | MAOBKDM4EHPGDADORA2BADORA1 | |
| SCHEMBL29779701 | 0.76 | MAOB (0.47) | GABRG2GABRB3GABRA5GABRA3MAOB | |
| SCHEMBL19555195 | 0.76 | KDM4E (0.49) | GABRG2GABRB3GABRA5GABRA3MAOB | |
| SCHEMBL29779702 | 0.76 | MAOB (0.47) | GABRG2GABRB3GABRA5GABRA3MAOB | |
| SCHEMBL19554588 | 0.76 | MAOB (0.47) | GABRG2GABRB3GABRA5GABRA3MAOB | |
| SCHEMBL19555127 | 0.73 | MAOB (0.43) | GABRG2GABRB3GABRA5GABRA3MAOB | |
| Hydrochloric Acid SCHEMBL28815182 | 0.73 | MAP4K4 (0.49) | GABRG2GABRB3GABRA5GABRA3MAOB | |
| Hydrochloric Acid SCHEMBL19554597 | 0.72 | TAAR1 (0.45) | GABRG2GABRB3GABRA5GABRA3MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11878979-B2 | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2024-01-23 | — | — | US | disclosed |
| CN-109311902-B | Substituted imidazo [1,2-b ] pyridazines, imidazo [1,5-b ] pyridazines, related compounds, and uses thereof | BIAL研发投资股份有限公司 | 2022-07-15 | — | — | CN | disclosed |
| US-20220185814-A1 | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2022-06-16 | — | — | US | disclosed |
| US-11168087-B2 | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2021-11-09 | — | — | US | disclosed |
| EP-3452481-A1 | SUBSTITUTED IMIDAZO[1,2-b | Lysosomal Therapeutics Inc. (US) | 2019-03-13 | — | — | EP | disclosed |
| CN-109311902-A | Substituted imidazo [1,2-b] pyridazine, substituted imidazo [1,5-b] pyridazine, related compound and their purposes in treatment medical disorder | 溶酶体治疗股份有限公司 | 2019-02-05 | — | — | CN | disclosed |
| US-9868742-B2 | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b] pyridazines, related compounds, and their use in the treatment of medical disorders | LYSOSOMAL THERAPEUTICS INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20170355702-A1 | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b] PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2017-12-14 | — | — | US | disclosed |
| WO-2017192930-A1 | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. (US) | 2017-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355702-A1 | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b] PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GBA2, GALC | GABRG2 841/4885GABRB3 1090/4885GABRA5 203/4885 |
| US-11168087-B2 | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders | GBA1, GBA2, GALC | GABRG2 841/4885GABRB3 1090/4885GABRA5 203/4885 |
| US-11878979-B2 | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders | GBA1, GBA2, GALC | GABRG2 841/4885GABRB3 1090/4885GABRA5 203/4885 |
| US-20220185814-A1 | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GBA2, GALC | GABRG2 841/4885GABRB3 1090/4885GABRA5 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.